AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026)
AtaiBeckley's quarterly Cash from Financing Activities came in at $821000.0 in Q1 2026, down 98.62% year-on-year from $59.6 million in Q1 2025, and down 98.62% quarter-over-quarter from $59.6 million in Q1 2025.
AtaiBeckley's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $59.7 million for Q3 2025.
- In Q3 2025, Cash from Financing Activities rose 1120.76% year-over-year to $59.7 million; the TTM figure through Sep 2025 stood at $127.3 million (up 4026.57% YoY), while the FY2024 annual figure was $5.4 million, up 164.32% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $821000.0, down from $59.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $59.6 million in Q1 2025, with the low at $821000.0 in Q1 2026.
- A 5-year average of $32.6 million and a median of $1.8 million in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities tumbled 817.68% in 2023 and soared 2279.45% in 2025, its largest moves.
- AtaiBeckley's Cash from Financing Activities stood at $1.7 million in 2021, then tumbled by 153.51% to -$922000.0 in 2022, then sank by 817.68% to -$8.5 million in 2023, then surged by 101.82% to $154000.0 in 2024, then jumped by 38694.81% to $59.7 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $59.7 million, $7.8 million, and $59.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | AtaiBeckley | 1.62 Bn | 1.62 Bn | - | 821,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 821,000.00 |
| Mar 31, 2026 | 821,000.00 |
| Sep 30, 2025 | 59.74 Mn |
| Sep 30, 2025 | 59.74 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Dec 31, 2024 | 154,000.00 |
| Dec 31, 2024 | 154,000.00 |
| Sep 30, 2024 | 4.89 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Jun 30, 2024 | 326,000.00 |
| Jun 30, 2024 | 326,000.00 |
| Dec 31, 2023 | -8.46 Mn |
| Dec 31, 2023 | -8.46 Mn |
| Jun 30, 2023 | -100,000.00 |
| Jun 30, 2023 | -100,000.00 |
| Mar 31, 2023 | 206,000.00 |
| Mar 31, 2023 | 206,000.00 |
| Dec 31, 2022 | -922,000.00 |
| Dec 31, 2022 | -922,000.00 |
| Sep 30, 2022 | 19.78 Mn |
| Sep 30, 2022 | 19.78 Mn |
| Jun 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 1.79 Mn |
| Mar 31, 2022 | 132,000.00 |
| Mar 31, 2022 | 132,000.00 |
| Dec 31, 2021 | 1.72 Mn |
| Dec 31, 2021 | 1.72 Mn |
| Sep 30, 2021 | 3.88 Mn |
| Sep 30, 2021 | 3.88 Mn |
| Jun 30, 2021 | 373.76 Mn |
| Jun 30, 2021 | 373.76 Mn |
| Mar 31, 2021 | 30.50 Mn |
| Mar 31, 2021 | 30.50 Mn |
| Dec 31, 2020 | 81.98 Mn |
| Dec 31, 2020 | 81.98 Mn |
| Sep 30, 2020 | 18.06 Mn |
| Sep 30, 2020 | 18.06 Mn |